HC Wainwright Has Negative Estimate for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Stoke Therapeutics in a research note issued to investors on Wednesday, November 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $0.04 for the year, down from their prior estimate of $0.29. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.83) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.84) EPS, Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($2.41) EPS and FY2028 earnings at ($1.33) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million.

Other analysts have also issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Jefferies Financial Group initiated coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. Chardan Capital restated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Finally, JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Stoke Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Stoke Therapeutics Stock Up 1.7%

Shares of NASDAQ STOK opened at $22.86 on Friday. The firm has a market cap of $1.31 billion, a P/E ratio of 34.12 and a beta of 1.32. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69. The company has a 50 day moving average of $26.47 and a 200 day moving average of $17.17.

Insider Activity

In related news, Director Edward M. Md Kaye sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total transaction of $750,000.00. Following the completion of the sale, the director directly owned 49,124 shares in the company, valued at approximately $1,473,720. The trade was a 33.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Barry Ticho sold 5,931 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32. Following the sale, the insider directly owned 7,195 shares of the company’s stock, valued at approximately $185,055.40. This represents a 45.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 186,607 shares of company stock valued at $4,224,210 in the last quarter. 9.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. AlphaQuest LLC purchased a new stake in Stoke Therapeutics in the first quarter worth about $72,000. US Bancorp DE increased its position in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after buying an additional 11,108 shares in the last quarter. Finally, Osaic Holdings Inc. raised its stake in shares of Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock worth $85,000 after buying an additional 5,427 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.